Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In adult patients undergoing cardiac surgery, does adding an sPIP block to standard care compared to standard care alone result in a smaller decrease in PFTs?
Postoperative pulmonary complications are a significant concern after cardiac surgery, with post-sternotomy pain contributing to impaired pulmonary function and increased risk of these complications. Parasternal intercostal plane blocks have recently emerged as a promising analgesic option for cardiac surgery, but their impact on pulmonary function tests (PFTs) has yet to be evaluated.
This prospective, single-center, double-blind, randomized controlled trial will recruit 100 adult patients undergoing elective cardiac surgery. Baseline pulmonary function, including FEV1, FVC, and PEF, will be measured preoperatively and reassessed on the first postoperative day to evaluate the primary outcome: percentage change in PFT values. Secondary outcomes include pain scores, opioid consumption, incidence of postoperative pulmonary complications during hospitalization, duration of cardiothoracic intensive care and hospital stays, and 30-day mortality.
This study aims to determine whether adding a superficial parasternal intercostal plane (sPIP) block to standard care better preserves pulmonary function in adult patients undergoing elective cardiac surgery.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment Arm | Active Comparator | In addition to standard care, the treatment arm will receive an ultrasound-guided bilateral single-shot superficial parasternal intercostal plane block at two levels. |
|
| Control Arm | Active Comparator | The control arm will receive standard care alone. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| superficial parasternal intercostal plane block | Procedure | Injection of 60 mL of bupivacaine 0.25% and epinephrine 2.5 µg mL-1 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage Change in Forced Expiratory Volume in the First Second (FEV1) | Percentage change in FEV1 (measured in litres) from baseline to the first postoperative day. | Baseline (preoperative) and first postoperative day |
| Percentage Change in Forced Vital Capacity (FVC) | Percentage change in FVC (measured in litres) from baseline to the first postoperative day. | Baseline (preoperative) and first postoperative day |
| Percentage Change in Peak Expiratory Flow (PEF) | Percentage change in PEF (measured in litres per second) from baseline to the first postoperative day. | Baseline (preoperative) and first postoperative day |
| Measure | Description | Time Frame |
|---|---|---|
| Pain scores, measured by Numeric Rating Scale (NRS) | Maximum pain NRS (0-10) recorded at various time intervals. | 0-8 hours, 8-16 hours, 16-24 hours, 24-48 hours, and 48-72 hours postoperatively |
| Opioid consumption, measured in Morphine Milligram Equivalents (MME) |
Not provided
Inclusion criteria:
Exclusion criteria:
Criteria For Discontinuing (Postoperative Exclusion Criteria):
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Shai Fein, MD, MHA | Contact | +972 52 8989630 | shaifein812@gmail.com | |
| Karam Azem, MD | Contact | +972 50 4705001 | dr.azem.k@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Shai Fein, MD, MHA | Rabin Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Rabin Medical Center, Beilinson Hospital | Recruiting | Petah Tikva | Israel | |||
| Rabin Medical Center |
Participant-level datasets and statistical code will be provided upon request.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010149 | Pain, Postoperative |
| ID | Term |
|---|---|
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010146 | Pain |
Not provided
Not provided
| ID | Term |
|---|---|
| D059039 | Standard of Care |
| ID | Term |
|---|---|
| D019984 | Quality Indicators, Health Care |
| D011787 | Quality of Health Care |
| D006298 | Health Services Administration |
| D017530 | Health Care Quality, Access, and Evaluation |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Standard care | Other | Operating Room: Anaesthesia will be induced using midazolam (0.1-0.15 mg kg-1), fentanyl (5-10 μg kg-1), and rocuronium (0.6-1.2 mg kg-1); then, after tracheal intubation, anaesthesia will be maintained using isoflurane at one MAC, along with continuous fentanyl (3-5 μg kg-1 h-1) and midazolam (20-50 μg kg-1 h-1). Additional boluses of fentanyl will be administered according to the anesthesiologist's discretion. Cardiothoracic Intensive Care Unit: Continuous fentanyl will be maintained until tracheal extubation. All patients will receive intravenous multimodal analgesic drugs around the clock, including paracetamol 3 g day-1 and dipyrone 3 g day-1. If pain persists, rescue doses of either intravenous tramadol or morphine will be administered. Cardiothoracic ward: The analgesic protocol includes around-the-clock intravenous paracetamol 3 g day-1 and dipyrone 3 g day-1. If pain continues, rescue doses of oral oxycodone will be administered. |
|
Opioid consumption measured in MME at various time intervals postoperatively. |
| 0-8 hours, 8-16 hours, 16-24 hours, 24-48 hours, and 48-72 hours postoperatively |
| Postoperative pulmonary complication, based on the European perioperative clinical outcome (EPCO) criteria | The incidence of postoperative pulmonary complications during current hospitalisation | 30 days |
| Length of stay | The length of cardiothoracic intensive care unit and hospital stay | 30 days |
| Mortality | Thirty-day mortality | 30 days |
| Not yet recruiting |
| Petah Tikva |
| Israel |
|
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |